Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

141. Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study (PubMed)

Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric Oxide in Patients with Schizophrenia: A pilot study Brain-derived neurotrophic factor (BDNF) and nitric oxide (NO) play multiple roles in the developing and adult CNS. Since BDNF and NO metabolisms are dysregulated in schizophrenia, we measured these markers simultaneously in the blood of schizophrenics and assessed their diagnostic accuracy.Thirty-eight patients with schizophrenia classified according to demographic (...) characteristics, symptomatologyand therapy and 39 age- and gender-matched healthy controls were enrolled. BDNF was determined by the ELISA technique while the concentration of nitrite/nitrate ([Formula: see text]) was measured by the colorimetric method.Serum BDNF levels were significantly lower (20.38±3.73 ng/mL, P = 1.339E-05), whilst plasma [Formula: see text] concentrations were significantly higher (84.3 (72-121) μmol/L, P=4.357E-08) in patients with schizophrenia than in healthy controls (25.65±4.32 ng

Full Text available with Trip Pro

2015 Journal of medical biochemistry

142. [Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. (PubMed)

[Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. The present research paper aims at assessing the effectiveness of a psychoeducational intervention in relatives' groups of patients with schizophrenia or schizoaffective disorder. It examines the possible influence of the intervention on family members as well as on the course of the patient illness. Of a total of 131 relatives, 83 consisted the experimental group and 48 the control group

2015 Psychiatrike = Psychiatriki

143. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review | CADTH.ca Find the information you need Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Published on: August 23, 2012 (...) Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from [CADTH Optimal Use Report; Volume 1, Issue 1B]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Schizophrenia is a mental illness that requires lifelong treatment 1 and is associated with symptoms that include hallucinations, delusions, cognitive impairment, disorganized thoughts, social withdrawal, and low motivation. 2

2015 CADTH - Health Technology Assessment

144. Lithium for schizophrenia. (PubMed)

Lithium for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary anti-psychotic drug treatment. In these cases, various add-on medications are used, among them lithium.To assess whether:1. Lithium alone is an effective treatment for schizophrenia, schizophrenia-like psychoses and schizoaffective psychoses; and2. Lithium augmentation of antipsychotic medication is an effective treatment for the same illnesses.In July 2012, we searched (...) the Cochrane Schizophrenia Group's Study-Based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. This search was updated on January 20, 2015. For the first version of the review, we also contacted pharmaceutical companies and authors of relevant studies to identify further trials and obtain original participant data.Randomised controlled trials (RCTs) of lithium compared with antipsychotics or placebo

2015 Cochrane

145. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. (PubMed)

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013 and August 26, 2015) which is based on regular searches of CINAHL, BIOSIS, AMED

Full Text available with Trip Pro

2015 Cochrane

146. Yoga versus standard care for schizophrenia. (PubMed)

Yoga versus standard care for schizophrenia. Yoga is an ancient spiritual practice that originated in India and is currently accepted in the Western world as a form of relaxation and exercise. It has been of interest for people with schizophrenia to determine its efficacy as an adjunct to standard-care treatment.To examine the effects of yoga versus standard care for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (November 2012 and January 29, 2015 (...) ), which is based on regular searches of MEDLINE, PubMed, EMBASE, CINAHL, BIOSIS, AMED, PsycINFO, and registries of clinical trials. We searched the references of all included studies. There were no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) including people with schizophrenia comparing yoga to standard-care control.The review team independently selected studies, quality rated these, and extracted

Full Text available with Trip Pro

2015 Cochrane

147. Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses | CADTH.ca Find the information you need Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Published on: December 15, 2011 Project Number: HO503 Product Line: Result type: Report The Canadian Agency for Drugs and Technologies in Health (...) (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The current project has several key components: Appraise the clinical and cost-effectiveness of combination and high-dose therapy with atypical antipsychotic agents for the treatment of schizophrenia Develop optimal use recommendations or advice Identify gaps in current

2015 CADTH - Optimal Use

148. Transcranial magnetic stimulation (TMS) for schizophrenia. (PubMed)

Transcranial magnetic stimulation (TMS) for schizophrenia. People with schizophrenia often experience symptoms which fail to fully respond to antipsychotic medication. Transcranial magnetic stimulation (TMS) has been proposed as a new treatment for people with schizophrenia, especially those who experience persistent auditory hallucinations.To estimate the effects of TMS alone, compared with sham TMS or with 'standard management' and any other comparison interventions in reducing psychotic (...) symptoms associated with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (June 2006, June 2008, April 2013). This register is compiled by methodical searches of MEDLINE, EMBASE, BIOSIS, CINAHL, Dissertation abstracts, LILACS, PSYNDEX, PsycINFO, RUSSMED, and Sociofile, and is supplemented with handsearching of relevant journals and numerous conference proceedings.We included all randomised controlled trials recruiting at least five participants and comparing TMS with sham TMS

Full Text available with Trip Pro

2015 Cochrane

149. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. (PubMed)

Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. Schizophrenia is a psychiatric disorder which involves distortions in thought and perception, blunted affect, and behavioural disturbances. The longer psychosis goes unnoticed and untreated, the more severe the repercussions for relapse and recovery. There is some evidence that early intervention services can help, and diagnostic techniques that could contribute to early (...) an individual will progress on to developing schizophrenia as opposed to other types of psychosis.To determine whether VBM applied to the brain can be used to differentiate schizophrenia from other types of psychosis in participants who have received a clinical diagnosis of first episode psychosis.In December 2013, we updated a previous search (May 2012) of MEDLINE, EMBASE, and PsycInfo using OvidSP.We included retrospective and prospective studies that consecutively or randomly selected adolescent

Full Text available with Trip Pro

2015 Cochrane

150. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review | CADTH.ca Find the information you need Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Published on: August 23, 2012 (...) Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from [CADTH Optimal Use Report; Volume 1, Issue 1B]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Schizophrenia is a mental illness that requires lifelong treatment 1 and is associated with symptoms that include hallucinations, delusions, cognitive impairment, disorganized thoughts, social withdrawal, and low motivation. 2

2015 CADTH - Health Technology Assessment

151. Social skills programmes for schizophrenia. (PubMed)

Social skills programmes for schizophrenia. Social skills programmes (SSP) are treatment strategies aimed at enhancing the social performance and reducing the distress and difficulty experienced by people with a diagnosis of schizophrenia and can be incorporated as part of the rehabilitation package for people with schizophrenia.The primary objective is to investigate the effects of social skills training programmes, compared to standard care, for people with schizophrenia.We searched (...) the Cochrane Schizophrenia Group's Trials Register (November 2006 and December 2011) which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. We inspected references of all identified studies for further trials.A further search for studies has been conducted by the Cochrane Schizophrenia Group in 2015, 37 citations have been found and are currently being assessed by review authors.We included all relevant randomised controlled trials

Full Text available with Trip Pro

2015 Cochrane

152. [Attributable risk of co-morbid substance use disorder in poor observance to pharmacological treatment and the occurrence of relapse in schizophrenia].

[Attributable risk of co-morbid substance use disorder in poor observance to pharmacological treatment and the occurrence of relapse in schizophrenia]. There are numerous risk factors involved in poor (incomplete) compliance to pharmacological treatment, and the associated relapse risk, for patients with schizophrenia. Comorbid substance use disorders are considered as among the most important ones, although how much their presence increase the risk of poorer observance (and higher risk (...) ) AND schizophrenia AND (French OR English [Language])" and "(Substance Abuse OR substance dependance) AND Outcome AND schizophrenia AND (French OR English [Language])". Studies were included if they describe two patients groups (schizophrenia with and without present substance use disorder) and assess the studied outcome. MetaWin(®) version 2 was used for the meta-analysis, while publication time bias relied on non-parametric correlation and the one linked to sample size was assessed through normal quantile

2015 L'Encephale

153. Supportive therapy for schizophrenia. (PubMed)

Supportive therapy for schizophrenia. Supportive therapy is often used in everyday clinical care and in evaluative studies of other treatments.To review the effects of supportive therapy compared with standard care, or other treatments in addition to standard care for people with schizophrenia.For this update, we searched the Cochrane Schizophrenia Group's register of trials (November 2012).All randomised trials involving people with schizophrenia and comparing supportive therapy with any other

2015 Cochrane

154. Lurasidone (Latuda) - schizophrenia

Lurasidone (Latuda) - schizophrenia Final Appraisal Recommendation Advice No: 0115 – February 2015 Lurasidone (Latuda ® ? ) 18.5 mg, 37 mg and 74 mg film-coated tablets Submission by Sunovion Pharmaceuticals Europe Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1142), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant (...) being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0115: Lurasidone (Latuda ® ? ) 18.5 mg, 37 mg and 74 mg film-coated tablets. February 2015. Recommendation of AWMSG Lurasidone (Latuda ® ? ) is recommended as an option for use within NHS Wales for the treatment of schizophrenia in adults aged 18 years and over.

2015 All Wales Medicines Strategy Group

155. Fluphenazine decanoate (depot) and enanthate for schizophrenia. (PubMed)

Fluphenazine decanoate (depot) and enanthate for schizophrenia. Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance. The benefits gained by long-acting preparations, however, may be offset by a higher incidence of adverse effects.To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms (...) of clinical, social and economic outcomes.We searched the Cochrane Schizophrenia Group's Trials Register (February 2011 and October 16, 2013), which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials.We considered all relevant randomised controlled trials (RCTs) focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations.We reliably selected

2015 Cochrane

156. First rank symptoms for schizophrenia. (PubMed)

First rank symptoms for schizophrenia. Early and accurate diagnosis and treatment of schizophrenia may have long-term advantages for the patient; the longer psychosis goes untreated the more severe the repercussions for relapse and recovery. If the correct diagnosis is not schizophrenia, but another psychotic disorder with some symptoms similar to schizophrenia, appropriate treatment might be delayed, with possible severe repercussions for the person involved and their family (...) . There is widespread uncertainty about the diagnostic accuracy of First Rank Symptoms (FRS); we examined whether they are a useful diagnostic tool to differentiate schizophrenia from other psychotic disorders.To determine the diagnostic accuracy of one or multiple FRS for diagnosing schizophrenia, verified by clinical history and examination by a qualified professional (e.g. psychiatrists, nurses, social workers), with or without the use of operational criteria and checklists, in people thought to have non-organic

Full Text available with Trip Pro

2015 Cochrane

157. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Article Text Causes and risk factors Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D 2/3 receptor occupancy following risperidone and olanzapine dose reduction Hiroyoshi Takeuchi , Gary Remington Statistics from Altmetric.com ABSTRACT FROM: Graff-Guerrero A, Rajji TK, Mulsant BH, et al . Evaluation of antipsychotic

2015 Evidence-Based Mental Health

158. Psychosis and schizophrenia

Psychosis and schizophrenia Psychosis and schizophrenia - NICE CKS Clinical Knowledge Summaries Share Psychosis and schizophrenia: Summary Psychosis is a disordered mental state characterized principally by positive symptoms such as hallucinations, delusions, and thought disorder. Psychotic symptoms are cardinal features of psychotic disorders such as schizophrenia, but may be caused by medicines and substance misuse, and by medical conditions such as sepsis in the elderly. Psychotic disorders (...) , including schizophrenia, are conditions in which psychosis occurs for a significant period of time. They may also be associated with negative symptoms (for example emotional blunting, reduced speech, loss of motivation, self neglect, and social withdrawal). With treatment, psychotic symptoms may resolve fully, recur intermittently with periods of remission between, or persist. Complications include: An increased risk of premature death due to an increased risk of suicide, cardiovascular disease

2015 NICE Clinical Knowledge Summaries

159. Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults

Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults Vraylar (Cariprazine) U.S. Department of Health and Human Services Search FDA Submit search Vraylar (Cariprazine) Vraylar (Cariprazine) Company: Forest Laboratories, LLC Application No.: 204370 Orig1 and Orig2 Approval Date: September 17, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

160. Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia

Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia Aristada (aripiprazole lauroxil) U.S. Department of Health and Human Services Search FDA Submit search Aristada (aripiprazole lauroxil) Aristada (aripiprazole lauroxil) Company: Alkermes, Inc. Application No.: 207533 Approval Date: October 5, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package